Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial

IMPORTANCE: Sodium-glucose cotransporter 2 inhibitors, such as dapagliflozin, promote renal glucose excretion and reduce cardiovascular (CV) deaths and hospitalizations for heart failure (HHF) among patients with type 2 diabetes. The relative CV efficacy and safety of dapagliflozin according to base...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:JAMA Cardiol
Egile Nagusiak: Zelniker, Thomas A., Raz, Itamar, Mosenzon, Ofri, Dwyer, Jamie P., Heerspink, Hiddo H. J. L., Cahn, Avivit, Goodrich, Erica L., Im, Kyungah, Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John P. H., Gause-Nilsson, Ingrid, Langkilde, Anna Maria, Sabatine, Marc S., Wiviott, Stephen D.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Medical Association 2021
Gaiak:
Original Investigation
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8047725/
https://ncbi.nlm.nih.gov/pubmed/33851953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2021.0660
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak